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Abstract
Purpose 18F-Florbetaben is a positron emission tomography
(PET) tracer indicated for imaging cerebral beta-amyloid de-
position in adult patients with cognitive impairment who are
being evaluated for Alzheimer’s disease and other causes of
cognitive decline. The present study examined ethnic compa-
rability of the plasma pharmacokinetics, which is the input to
the brain, between Caucasian and Japanese subjects.
Methods Two identical phase I trials were performed in 18
German and 18 Japanese healthy volunteers to evaluate the
plasma pharmacokinetics of a single dose of 300 MBq 18F-
florbetaben, either of low (≤5μg, LD) or high (50–55μg, HD)
mass dose. Pharmacokinetic parameters were evaluated based
on the total 18F radioactivity measurements in plasma follow-
ed by metabolite analysis using radio-HPLC.
Results The pharmacokinetics of 18F-florbetaben was charac-
terized by a rapid elimination from plasma. The dose-
normalized areas under the curve of 18F-florbetaben in plasma
as an indicator of the input to the brain were comparable
between Germans (LD: 0.38 min/l, HD: 0.55 min/l) and
Japanese (LD: 0.35 min/l, HD: 0.45 min/l) suggesting ethnic
similarity, and the mass dose effect was minimal. A polar
metabolite fraction was the main radiolabelled degradation
product in plasma and was also similar between the doses
and the ethnic groups.
Conclusion Absence of a difference in the pharmacokinetics
of 18F-florbetaben in Germans and Japanese has warranted
further global development of the PET imaging agent.
Keywords Florbetaben . PET . Alzheimer’s disease .
Beta-amyloid . Pharmacokinetics
Introduction
Positron emission tomography (PET) imaging of cerebral
beta-amyloid deposition is valuable for adult patients with
cognitive impairment who are being evaluated for
Alzheimer’s disease (AD) and other causes of cognitive de-
cline as well as for evaluation of treatments aimed at reducing
amyloid burden. While 11C-Pittsburgh compound B (PIB) has
been most widely used as a PET imaging agent of cerebral
beta-amyloid deposition, the short half-life of 11C (T1/2=
20 min) reduces clinical practicality and has prompted devel-




oxy}-stilbene (previously also known as BAY 94-9172). Ini-
tial clinical studies have revealed promising results regarding
the diagnostic capability of 18F-florbetaben as it accumulated
in the cerebral cortex of patients with AD, while very low
uptake was observed in normal subjects and in patients with
frontotemporal dementia [1, 2]. Those reports triggered global
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clinical development of 18F-florbetaben as a PET diagnostic
agent [3], and the initial results were confirmed in a pivotal
histopathology study [4], leading to recent approval in Europe
and the USA (NeuraCeq™).
Plasma pharmacokinetics, which is the input function to
organs, is of importance for evaluation of the brain uptake of
the PET agent, especially in cases of kinetic analysis of the
brain time-activity curves [5]. Because ethnicity may affect
the pharmacokinetics of a drug [6, 7], it is essential to confirm
similar plasma pharmacokinetics of 18F-florbetaben in differ-
ent ethnic populations as a basis for further global develop-
ment on multiple races and ethnicities that are designed to
evaluate the brain accumulation in various patients and normal
subjects. The present report compares the plasma time course
of 18F-florbetaben and its labelled metabolites, blood to plas-
ma ratio and urinary excretion following intravenous injection
in healthy German and Japanese subjects.
Materials and methods
Study design
Two identical studies were carried out as phase I clinical trials
of 18F-florbetaben in healthy subjects which were conducted
at the University of Leipzig, Leipzig, Germany and at the
Institute of Biomedical Research and Innovation (IBRI), Ko-
be, Japan. The pharmacokinetic data of plasma and urine were
acquired as well as the safety data. Also the radioactivity
accumulation and distribution in the brain and the whole body
was imaged using a PET camera, the results of which will be
reported in separate publications.
At each site, a total of 24 subjects were recruited. The first
12 subjects were intravenously injected with either 300±
60 MBq of 18F-florbetaben of low mass dose (LD: <5 μg)
(n=9) or placebo (PL: vehicle) (n=3), in a single-blind ran-
dom manner. After safety data were assessed and the sponsor
and the investigator confirmed that no safety concerns had
been raised, the latter 12 subjects were intravenously injected
with either 300±60MBq of 18F-florbetaben of highmass dose
(HD: >50 and ≤55 μg) (n=9) or placebo (vehicle) (n=3), in a
single-blind random manner. The HD study was designed to
examine the mass dose effect on pharmacokinetics and to
demonstrate the practicability of delivery of 18F-florbetaben
from a production site to distant PET imaging sites, for which
product vials containing higher radioactivity are produced to
compensate for the radioactive decay during the transporta-
tion. As a result a higher amount of coexisting non-radioactive
florbetaben remains as a high mass dose.
All studies were conducted based on Good Clinical Prac-
tice in accordance with the Declaration of Helsinki and its
revisions. At each site, the study protocol was reviewed and
approved by each Institutional Review Board (University of
Leipzig Ethics Committee and IBRI Institutional Review
Board). All subjects provided written informed consent before
participating in the study after the study procedures had been
fully explained both orally and in written form.
Subjects
The participants were either of German or Japanese ethnicity
and were healthy subjects aged greater than or equal to
55 years, and women were without child-bearing potential.
They underwent screening tests that covered medical and
family history, physical and neurological examination, ECG,
blood and urine test, neuropsychological tests and a brainMRI
scan. They were eligible if the neuropsychological scores
were within the normal range and if the MRI was age appro-
priate except for very mild medial temporal lobe atrophy and
mild to moderate age-related white matter lesions.
Exclusion criteria were a history of significant psychiatric
or neurological illness, history of drug or alcohol abuse,
cancer within 5 years, positive test for human immunodefi-
ciency virus (HIV), hepatitis B or hepatitis C virus or syphilis
and any significant or unstable medical conditions such as
unstable angina, recent myocardial infarction, cardiac failure,
chronic renal failure, chronic liver disease, severe pulmonary
disease, blood disorders, poorly controlled diabetes and
chronic infection. They were also ineligible if the haemato-
logical or biochemical parameters were outside the normal
range and considered clinically significant by the investigator.
Synthesis of 18F-florbetaben
18F-florbetaben was manufactured and quality tested based on
GoodManufacturing Practice for investigational drugs at each
study site, which was audited by Bayer HealthCare. Briefly,
18F was produced by bombardment of 18O-enriched water
with protons using an in-house cyclotron and trapped in a
cartridge and was then eluted with Kryptofix K2.2.2 and
K2CO3 into a reaction vessel. The precursor compound
(BOC-stilbene mesylate) was added and the mixture was
heated for 18F labelling, followed by cooling and hydrolysis
[8]. On purification of 18F-florbetabenwith radio-HPLC of the
reaction mixture, the product fraction was fixed on a solid
phase extraction cartridge, which was subsequently eluted
with ethanol into the formulation. For the HD study, 50 μg
of standard non-radioactive florbetaben was added to the
formulation. For the LD study, no carrier was added. For the
PL study, the injection was formulated in the same way
without 18F-florbetaben.
The study drug was tested for quality. Identification of 18F
was tested with gamma spectroscopy and half-life measure-
ment, and the radionuclidic purity was ≥99 %. Identification
of 18F-florbetaben was tested using HPLC with florbetaben as
the reference standard, and the radiochemical purity was
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specified as ≥90 %, the actual value being 94.1±1.6 % for
Germans and 92.9±1.6 % for Japanese. The pH was between
4.5 and 8.5. Residual solvents were specified as methanol
≤3,000 μg/ml, acetonitril ≤410 μg/ml and dimethyl
sulphoxide (DMSO) ≤5,000 μg/ml. Residual Kryptofix 222
was <50 μg/ml.
Pharmacokinetic assessments
The study drug (LD, HD or PL) was administered to the
subjects as a slow intravenous injection to minimize the effect
of ethanol, lasting 1 min in Germans and 2 min in Japanese,
followed by a 10-ml saline flush. Venous blood was sampled
before the injection and 2.5, 5, 10, 20, 30, 50, 70, 90, 120, 180,
240 and 360 min after start of injection for measurement of
radioactivity concentration of whole blood and plasma using a
gamma counter as well as for the analysis of labelled metab-
olites in plasma using radio-HPLC. Venous blood was also
sampled in addition at 480, 720 and 1,440 min post-injection
(p.i.) for radioactivity measurement only. In the Japanese
study, metabolite analysis was omitted for the 5-, 20-, 50-
and 90-min samples. The sampled blood volume was 2 ml for
radioactivity measurement with additional 5 ml for metabolite
analysis.
The blood samples in the German study were processed as
described previously [9]. Briefly, 5 ml blood was centrifuged
at 2,500g for 5 min to generate plasma and then submitted to
protein precipitation by addition of 2 volumes CH3CN and
centrifugation at 6,000g for 10 min. The resulting supernatant
was analysed by HPLC [column Luna Phenyl-Hexyl 250×10
mm, 5 μm, flow 6 ml/min, injection volume >5 ml, gradient
20 % CH3CN (80 % water) increasing to 90 % at 12.1 min,
increasing to 100 % at 13 min, 20 % at 13.1 min and 20 % at
15 min]. Essentially the same technique was used in the
Japanese study except that each of the two centrifugation
processes was done at 4,200g for 10 min. The HPLC
radiodetector in the German study was 3×3” NaI detector in
combination with GABI star from Raytest (Straubenhardt,
Germany), while that in the Japanese study was US2000
(1 in. diameter NaI) of Universal Giken (Kanagawa, Japan).
Urine was collected in the intervals 0–135, 135–300, 300–
435 (for Japanese only) and 435–700 min for measurement of
volume and radioactivity concentration using a gamma coun-
ter. Aliquots of the first two time intervals (135 and 300 min
p.i.) were also analysed for radioactive metabolites using
radio-HPLC in the same way as described above to obtain
the fraction of 18F-florbetaben and labelled metabolites.
The plasma radioactivity data were corrected for the radio-
active decay to obtain both the total 18F radioactivity concen-
tration and the 18F-florbetaben radioactivity concentration
after correction for the labelled metabolites at each time point.
Then descriptive pharmacokinetic parameters were derived,
including maximum plasma concentration normalized by the
injected activity (Cmax/D), area under concentration vs time
curve from zero up to the last measurable data point normal-
ized by the injected activity (AUC0-tlast/D) and blood to
plasma ratio of total radioactivity. The results were expressed
as geometric mean and coefficient of variation (CV) and were
compared between LD and HD as well as between Germans
and Japanese. No mathematical kinetic modelling analysis
was carried out.
Statistical tests were carried out using two-way analysis of
variance (ANOVA) with an ethnicity by mass dose interaction
term to examine the effects of ethnicity and mass dose on the
logarithm of AUC0-tlast/D of plasma total radioactivity and
18F-florbetaben concentration as well as on the logarithm of
AUC of labelled polar metabolite per injected activity up to
120 min. The level of significance was set to p=0.05 without
consideration of multiple comparisons. No statistical tests
were carried out on Cmax/D because it depends on the injection
speed, which was not sufficiently controlled in this study.
The urinary radioactivity data were also analysed to com-
pute the percentage urinary excretion of the injected 18F
radioactivity both in the form of 18F-florbetaben and labelled
metabolites for each interval of the urine collection.
Safety assessments
Safety data were acquired on symptoms and signs, ECG and
blood and urine test before and 6, 24 and 48 h p.i. and
additionally on ECG at 2 h 15 min and 12 h.
Results
Participants
Table 1 summarizes the demographics of the subjects. All
German subjects were Caucasian, and all Japanese subjects
were Asian. While the age was comparable, the average body
weight of the Japanese subjects was 19 % less than the
Germans.
Pharmacokinetics
The plasma concentration of total 18F radioactivity was at
maximum at the first sampling time point (2.5 min) in most
subjects and decreased rapidly thereafter. Figure 1 illustrates
the total plasma 18F radioactivity curve for each ethnic group
and for each mass dose. Table 2 presents the pharmacokinetic
parameters derived from the total plasma 18F radioactivity
concentration vs time curves. No substantial difference was
observed between LD and HD. Japanese showed a higher
Cmax/D value than the Germans possibly due to the longer
injection duration in Japanese subjects. No significant
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difference was observed in AUC0-tlast/D between the ethnic-
ities or between LD and HD. No significant interaction effect
between ethnicity and mass dose was observed.
The ratio of the blood to plasma radioactivity concentration
was 0.75 for Germans and 0.80 for Japanese at 2.5 min and
gradually decreased toward 180 min, being approximately
0.7 at 70 min. No remarkable difference was observed be-
tween LD and HD or between the ethnicities.
Figure 2 illustrates the radio-HPLC output of the plasma
metabolite analysis. At 2.5 min p.i. most of the radioactivity in
the plasma was 18F-florbetaben (on average, 83 and 78 % for
LD and HD in Germans and 80 and 85 % for LD and HD in
Japanese, respectively), which decreased rapidly at 30min p.i.
paralleled by an increase in the metabolite fraction (18 and
12 % for LD and HD in Germans and 8 and 11 % for LD and
HD in Japanese). A polar metabolite fraction was the main
radiolabelled degradation product in plasma. A small radioac-
tivity peak was also detected that eluted directly prior to 18F-
florbetaben both in Germans and Japanese and was identified
as N-desmethyl 18F-florbetaben based on co-elution with an
authentic reference standard in the German study.
Table 3 represents the pharmacokinetic parameters of the
plasma 18F-florbetaben concentration obtained from the data
of the plasma parent fraction. Figure 3 depicts plasma con-
centration curves of unchanged 18F-florbetaben, 18F-labelled
polar metabolites and N-desmethyl 18F-florbetaben for each
ethnic group and for eachmass dose. The pharmacokinetics of
18F-florbetaben was characterized by rapid elimination from
plasma as 18F-labelled polar metabolites appeared and in-
creased in the same time frame. When two-way ANOVA
was carried out on the AUC0-tlast/D of plasma
18F-florbetaben
concentration (%ID/l), a small but significant difference
(p<0.05) was observed between LD and HD, while no sig-
nificant difference was observed between Germans and Japa-
nese. Statistical analysis on the AUC (0–120 min) of the 18F-
labelled polar metabolite (Fig. 3) also showed a small but
significant difference (p<0.05) between LD and HD, while
no significant difference was observed between Germans and
Japanese. No significant interaction effect between ethnicity
and mass dose was observed.
Table 4 summarizes the urinary excretion of total 18F
radioactivity, 18F-florbetaben and 18F polar metabolites
expressed as per cent of injected activity for each interval of
urine collection. Approximately 13–20 % of the injected
radioactivity dose was excreted renally during the first
135 min. Almost all radioactivity in the urine was excreted
as metabolites, whereas only trace amounts (0.1–0.2 %) of the
radioactivity dose were detected as 18F-florbetaben in the first
collection interval from 0 to 135 min. Of the detected metab-
olites, a polar metabolite fraction eluted from the column
contributed to almost all radioactivity. This fractionwas prom-
inent in all collection intervals. Overall, approximately 26–
36 % of the administered radioactivity dose was excreted in
urine up to 12 h p.i. Only around 0.1 % of the dose was
recovered as unchanged 18F-florbetaben in urine and excre-
tion occurred only in the first collection interval (0–135 min)
when 18F-florbetaben concentrations were highest in plasma.
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Fig. 1 Total 18F radioactivity concentration time profile in plasma (de-
cay-corrected)
Table 2 Pharmacokinet-





ID injected dose, Mean
geometric mean, CV co-
efficient of variation, LD




Mean (CV) Mean (CV)
Germans
LD 3.48 (42.0 %) 10.1 (21.3 %)
HD 6.00 (34.0 %) 10.1 (37.8 %)
Japanese
LD 6.74 (43.7 %) 10.9 (12.8 %)
HD 8.81 (45.8 %) 12.0 (12.6 %)
Table 1 Demographics and
injections
LD low mass dose,HD high mass
dose, PL placebo
Parameters Germans Japanese
Number of subjects (LD, HD, PL) 24 (9, 9, 6) 24 (9, 9, 6)
Sex, male/female 12/12 17/7
Age, mean (range) 62.4 (55–75) 61.5 (55–71)
Weight, kg, mean (range) 75.0 (52.0–92.2) 60.9 (42.0–75.7)
Height, cm, mean (range) 170 (155–185) 163 (145–177)
Mean injected activity (MBq) LD, HD, PL 309, 293, 0 309, 296, 0
Mean injected dose (μg) LD, HD, PL 0.8, 50, 0 2.5, 53.3, 0
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No ethnic difference or dose effect was observed in the urinary
excretion.
Safety
Most frequently reported treatment-emergent adverse events
were related to injection site reactions including irritation,
discomfort or pain observed in four PL, six LD and three
HD German subjects and in four PL, eight LD and eight HD
Japanese subjects (of six PL, nine LD and nine HD subjects,
respectively, for both ethnicities). They were all mild and soon
disappeared.
Discussion
In the present study, German and Japanese healthy subjects
were administered either LD or HD of 18F-florbetaben. The
mean dose was 2.5 μg for LD and 53.3 μg for HD in the
Japanese study and 0.8 μg and approx. 50 μg for the German
study, respectively (Table 1). Thus, a factor of 20- to 60-fold
difference in the meanmass dose was present between LD and
HD.
After intravenous administration of 300 MBq of 18F-
florbetaben to healthy subjects, maximum plasma concentra-
tions of total radioactivity were observed at the first time point
after the end of the infusion, i.e. at about 2.5 min after the start
of the injection. Thereafter, total radioactivity concentrations
declined rapidly in plasma, probably due to rapid and pro-
nounced distribution into the whole-body tissues as well as
due to metabolic clearance. Those findings are compatible
with the previous report of the proof of mechanism study
[9]. No difference was observed between LD and HD or
between the ethnic groups (Fig. 1, Table 2).
A blood to plasma radioactivity ratio ranging 0.75 to 0.80
on averagewas observed at the first sampling time point of
2.5 min. This ratio was greater than 0.54 (corresponding to 1
minus measured haematocrit of 0.46), which might indicate
that florbetaben weakly binds to or is distributed into red
blood cells. There was a trend of a decreasing blood to plasma
ratio up to 180 min p.i. This could be due to a different blood
to plasma partitioning of the polar metabolite fraction, which
Fig. 2 Representative HPLC radiochromatogram of the plasma samples at 2.5, 10 and 30 min p.i. of 18F-florbetaben in a German and Japanese subject
Table 3 Pharmacokinetic parameters of 18F-florbetaben in plasma after
single intravenous injection of 18F-florbetaben
Cmax/D AUC0-tlast/D
(%ID/l) (%ID·h/l)
Mean (CV) Mean (CV)
Germans
LD 1.97 (41.3 %) 0.640 (32.0 %)
HD 4.64 (35.7 %) 0.924 (35.4 %)
Japanese
LD 5.30 (59.3 %) 0.587 (44.3 %)
HD 6.46 (108 %) 0.745 (41.4 %)
ID injected dose, Mean geometric mean, CV coefficient of variation, LD
low mass dose, HD high mass dose
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represents almost all radioactivity in blood and plasma at later
time points.
18F-Florbetaben was rapidly metabolized with appearance
of labelled metabolites in plasma, the largest of which was one
polar metabolite fraction that contributed to almost all radio-
activity in plasma at later sampling time points (30 min p.i.
and thereafter) (Fig. 2). This polar metabolite was observed to
a similar extent in Germans and Japanese as well as for LD
and HD injections. The structure of the polar metabolite is
unknown but may result from cleavage of the 18F-labelled
polyethylene glycol (PEG) side chain [9]. In addition to this
polar metabolite peak, a minor radiopeak was detected on the
radiochromatogram at a retention time between 10 and
11 min. Co-chromatography with an authentic reference stan-
dard suggests that this peak represents an N-desmethylated
compound of 18F-florbetaben, which is the primary amine
derivative of 18F-florbetaben. Overall, the concentrations of
N-desmethyl 18F-florbetaben were small as compared to the
polar metabolite fraction.
Plasma pharmacokinetics of 18F-florbetaben was obtained
using information from the radio-HPLC metabolite fraction
data and the total radioactivity data (Fig. 3), from which
pharmacokinetic parameters were assessed (Table 3). Consid-
ering the methodological limitations of the quantification of a
microdose amount of 18F-florbetaben (i.e. estimation based on
the radio-HPLC and the total 18F radioactivity in plasma), the
estimated concentrations and derived pharmacokinetic param-
eters provide only explorative and orienting information. Nev-
ertheless, the evaluations are supportive to describe the basic
pharmacokinetic properties of 18F-florbetaben since the plas-
ma 18F-florbetaben concentration was followed up to the time
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Fig. 3 Mean plasma
concentration time profiles of 18F-
florbetaben and its metabolites
(decay-corrected)
Table 4 Urinary excretion of total 18F radioactivity, 18F-florbetaben and 18F polar metabolites expressed as per cent of injected activity (mean ± SD)
Interval Total 18F 18F-florbetaben 18F polar metabolites
LD HD LD HD LD HD
Germans
0–135 min 12.7±2.56 (9) 14.0±4.14 (8) 0.194±0.130 (7) 0.182±0.063 (7) 11.6±2.33 (7) 12.7±4.18 (8)
135–240 min 4.94±1.84 (9) 5.25±1.85 (8) 0.033±0.022 (3) 0.034±0.026 (6) 4.38±0.67 (7) 4.65±1.63 (8)
0-tlast
a 26.4±4.21 (9) 30.8±6.77 (8)
Japanese
0–135 min 19.5±7.9 (9) 17.4±6.1 (9) 0.117±0.038 (8) 0.111±0.044 (9) 18.7±7.6 (9) 16.6±5.8 (9)
135–305 min 5.3±2.9 (9) 8.2±3.6 (9) ND ND 5.0±2.7 (9) 7.9±3.4 (9)
305–435 min 3.7±1.1 (9) 4.9±0.6 (9)
435–720 min 6.2±4.9 (8) 5.2±1.3 (9)
0–720 min 33.1±7.2 (8) 35.7±5.1 (9)
Mean±SD (n)
ND not detected, LD low mass dose, HD high mass dose
a Last collection time ranged between 5.0 and 12.3 h
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The dose-normalized Cmax (Cmax/D) had a large variation
with mean values showing an about twofold difference be-
tween the ethnicities or mass doses (Table 3), which is pre-
sumably related to the difference in the injection speed.
The AUC0-tlast/D of plasma
18F-florbetaben concentration
(%ID/l) showed a small (about 1.4-fold) but significant dif-
ference between LD and HD, while no difference was ob-
served between Germans and Japanese. No significant differ-
ence was observed for AUC0-tlast/D of plasma total activity
concentration. Thus, there is a possibility of slight mass dose
effect on the pharmacokinetics, although saturation of meta-
bolic enzymes, such as cytochrome P450, is unlikely because
it usually requires doses in the milligram or even gram range
depending on the respective Km values. In fact, the mean per
cent of unchanged tracer relative to total 18F radioactivity in
plasma decreased at a similar rate in both tracer mass dose
groups at early sampling time points. Therefore, allowing for
methodological limitations of the quantification, the present
data indicate that the mass dose effect is minimal within a
tracer mass dose range of up to 50 μg. Thus, the practicability
of high mass dose injection is not impaired, which is relevant
to remote delivery of the PET drug that requires a longer
shipment time resulting in decreased specific radioactivity
due to decay. In any case, the plasma concentration is can-
celled out if the PET images are scaled to a reference region
for visual interpretation or if the standard uptake value ratio
(ratio of uptake to reference region) is used for quantitative
evaluation of the cortical uptake.
In addition to plasma analysis, urine samples were analysed
to estimate the proportion of radioactivity dose excreted in the
urine. The data suggest that approx. 26–36 % of the injected
activity was excreted renally up to 12 h. Almost the entire
radioactivity was excreted as polar metabolites and only trace
amounts of intact 18F-florbetaben were recovered in urine.
The polar metabolite fraction, which was also the prominent
species in plasma, represented the majority of radioactivity in
urine, suggesting that these metabolites are excreted renally.
Lister-James et al. [10] have reported the pharmacokinetics
of 18F-labelled florbetapir, which is another beta-amyloid
tracer having a structure similar to 18F-florbetaben, with a
benzene ring of 18F-florbetaben replaced by a pyridine ring.
In their human study, 18F-labelled florbetapir rapidly cleared
from blood leaving <5 % of injected activity in blood after
20 min, and the blood radioactivity derived mainly from polar
metabolites by 90 min p.i. Urinary excretion of radioactivity
was approximately 17 % of the dose by 200 min p.i. The
pharmacokinetic results of 18F-florbetapir are similar to the
data observed with 18F-florbetaben suggesting similar under-
lying pharmacokinetic processes for both tracers.
In the present study, venous plasma concentration of radio-
activity and 18F-florbetaben was measured and the AUC was
evaluated as a bulk input to the brain, which is an important
factor for the radioactivity uptake by the brain in a later phase
(e.g. 90 min p.i.) to be imaged for diagnosis of amyloid
deposition [1]. Arterial plasma concentration was not mea-
sured because tracer kinetic analysis was out of the scope of
the present study and accurate arterial input function was not
necessary. In a previous study, arterial plasma concentration of
radioactivity and 18F-florbetaben was measured and a repre-
sentative case was reported [9]. The venous concentration
obtained in the present study was comparable to the arterial
data reported in the previous study except for the early phase
(2.5 min p.i.) when the venous samples showed lower values
than the arterial data due to dispersion. Furthermore, the 18F-
florbetaben fraction of venous plasma radioactivity mea-
sured in the present study was very similar to those of
arterial data [9].
Conclusion
The pharmacokinetics of 18F-florbetaben is similar between
German and Japanese subjects. After intravenous injection,
18F-florbetaben distributes into whole-body tissues and is
rapidly eliminated from plasma. Within the methodological
limits of quantification, the effect of mass dose on the phar-
macokinetics of 18F-florbetaben is minimal up to about 50 μg
in healthy subjects. A polar metabolite fraction constitutes the
main radiolabelled degradation product in plasma. The present
study confirmed ethnic similarity of 18F-florbetaben pharma-
cokinetics observed in plasma and urine as a basis of further
global studies that evaluate and compare the brain accumula-
tion in various races and ethnicities.
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